Altium Capital Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Altium Capital Management’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-625,469	Closed	-$3.07M	–	173
2021 Q3	$3.07M	Buy	625,469 +154,520	+33%	+$750K	0.81%	53
2021 Q2	$2.49M	Buy	470,949 +20,949	+5%	+$108K	0.58%	72
2021 Q1	$2.16M	Buy	+450,000	New	+$2.35M	0.6%	70

Altium Capital Management's ADMS Position: Q4 2021 in Review

Altium Capital Management sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 625,469 shares — an estimated $3.07M sold.

Altium Capital Management first reported a position in ADMS in Q1 2021 and held it in 3 quarters. The position peaked at $3.07M in Q3 2021. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.

Altium Capital Management reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Altium Capital Management sold 625,469 Adamas Pharmaceuticals shares in Q4 2021, an estimated $3.07M.
Altium Capital Management first reported a position in Adamas Pharmaceuticals in Q1 2021 and held it in 3 quarters.
Altium Capital Management's Adamas Pharmaceuticals position peaked at $3.07M in Q3 2021.
0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.

Based on Altium Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.